Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Titel:
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Auteur:
Reck, Martin Schenker, Michael Lee, Ki Hyeong Provencio, Mariano Nishio, Makoto Lesniewski-Kmak, Krzysztof Sangha, Randeep Ahmed, Samreen Raimbourg, Judith Feeney, Kynan Corre, Romain Franke, Fabio Andre Richardet, Eduardo Penrod, John R. Yuan, Yong Nathan, Faith E. Bhagavatheeswaran, Prabhu DeRosa, Michael Taylor, Fiona Lawrance, Rachael Brahmer, Julie